Share

August 2015; 1 (2) ArticleOpen Access

Tongue atrophy and fasciculations in transthyretin familial amyloid neuropathy

An ALS mimicker

Namita A. Goyal, Tahseen Mozaffar
First published July 30, 2015, DOI: https://doi.org/10.1212/NXG.0000000000000018
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1315

Share

Article Information

vol. 1 no. 2 e18
DOI: 
https://doi.org/10.1212/NXG.0000000000000018
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2376-7839
History: 
  • Received May 18, 2015
  • Accepted in final form June 24, 2015
  • First Published July 30, 2015.
Copyright & Usage: 
© 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Namita A. Goyal, MD and
    2. Tahseen Mozaffar, MD
  1. Namita A. Goyal, MD and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Dr. Goyal has received clinical research support from Alnylam and ISIS Pharmaceuticals for ongoing clinical experimental trials in FAP.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Tahseen Mozaffar, MD
    3. Scientific Advisory Boards:

    1. On Medical and Scientific Advisory Board for the Myositis Association, Genzyme Genetics, Idera Pharmaceuticals, and Ultragenyx

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Received travel reimbursement for advisory board meeting for 1) Genzyme Corporation; 2) Biomarin; and 3) Amicus

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1) Commercial or non-profit entity: Amicus, 2) Commercial or non-profit entity: Biomarin, 3) Commercial or non-profit entity: Genzyme, 4) Commercial or non-profit entity: Sarepta and 5) Commercial or non-profit entity: Ultragenyx

    Speakers' Bureaus:

    1. 1) Commercial or non-profit entity: Genzyme Corporation

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1) Commercial or non-profit entity: Alnylam 2) Commercial or non-profit entity: Alexion 3) Commercial or non-profit entity: Amicus 4) Commercial or non-profit entity: Biomarin 5) Commercial or non-profit entity: CSL 6) Commercial or non-profit entity: Genzyme 7) Commercial or non-profit entity: ISIS 8) Commercial or non-profit entity: GSK 9) Commercial or non-profit entity: Novartis 10)Commercial or non-profit entity: Ultragenyx

    Research Support, Government Entities:

    1. NIH Funding (co-investigator on R01NS049203) 2009-onwards

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (N.A.G., T.M.) and Department of Orthopaedic Surgery (T.M.), University of California, Irvine.
  1. Correspondence to Dr. Goyal: namitag{at}uci.edu
View Full Text

Article usage

Article usage: July 2015 to February 2023

AbstractFullPdfSource
Jul 20151565Highwire
Aug 201560750585Highwire
Sep 201517421117Highwire
Oct 201512228124Highwire
Nov 2015451716Highwire
Dec 2015323411Highwire
Jan 2016252013Highwire
Feb 2016341118Highwire
Mar 2016431725Highwire
Apr 2016251222Highwire
May 201626804Highwire
Jun 20161383Highwire
Jul 201617102Highwire
Aug 201615157Highwire
Sep 2016221511Highwire
Oct 201611105Highwire
Nov 20168157Highwire
Dec 201691111Highwire
Jan 2017131311Highwire
Feb 20176158Highwire
Mar 201715192Highwire
Apr 20171191Highwire
May 20175116Highwire
Jun 201751212Highwire
Jul 2017885Highwire
Aug 2017762Highwire
Sep 2017238Highwire
Oct 20171169Highwire
Nov 201714515Highwire
Dec 20170125Highwire
Jan 201802679Highwire
Feb 201812311Highwire
Mar 20180284Highwire
Apr 20180182Highwire
May 20181332Highwire
Jun 20180804Highwire
Jul 20181513Highwire
Aug 20182828Highwire
Sep 201823797Highwire
Oct 201805994Highwire
Nov 2018064111Highwire
Dec 2018283418Highwire
Jan 201913529Highwire
Feb 2019619215Highwire
Mar 2019418022Highwire
Apr 2019616116Highwire
May 2019122823Highwire
Jun 2019520629Highwire
Jul 2019224417Highwire
Aug 2019026332Highwire
Sep 201921928Highwire
Oct 2019121717Highwire
Nov 2019320514Highwire
Dec 201922119Highwire
Jan 2020224712Highwire
Feb 2020322616Highwire
Mar 2020219913Highwire
Apr 2020522314Highwire
May 2020320418Highwire
Jun 2020122110Highwire
Jul 202012356Highwire
Aug 202021739Highwire
Sep 2020126410Highwire
Oct 2020323228Highwire
Nov 2020026218Highwire
Dec 2020119715Highwire
Jan 2021023411Highwire
Feb 2021225410Highwire
Mar 2021527229Highwire
Apr 202112129Highwire
May 2021342217Highwire
Jun 202122379Highwire
Jul 2021419216Highwire
Aug 202112078Highwire
Sep 2021319120Highwire
Oct 2021324424Highwire
Nov 202125519Highwire
Dec 20213947Highwire
Jan 202211855Highwire
Feb 2022718620Highwire
Mar 2022423413Highwire
Apr 202261978Highwire
May 2022320515Highwire
Jun 2022121723Highwire
Jul 2022132611Highwire
Aug 202224198Highwire
Sep 2022339729Highwire
Oct 2022325119Highwire
Nov 2022933930Highwire
Dec 2022220920Highwire
Jan 2023522114Highwire
Feb 2023427718Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles